Gene Enrichment Analysis of Astrocyte Subtypes in Psychiatric Disorders and Psychotropic Medication Datasets

• Published in: Cells (Basel, Switzerland) Switzerland), 2022-10, Vol.11 (20), p.3315
• Main Authors: Zhang, Xiaolu, Wolfinger, Alyssa, Wu, Xiaojun, Alnafisah, Rawan, Imami, Ali, Hamoud, Abdul-Rizaq, Lundh, Anna, Parpura, Vladimir, McCullumsmith, Robert E, Shukla, Rammohan, O'Donovan, Sinead M
• Format: Article
• Language: English
• Subjects: Analysis; Antidepressants; Antidepressive Agents - therapeutic use; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Antipsychotics; astrocyte subtype; Astrocytes; Biochemical analysis; Care and treatment; Chronic effects; Disease; Dosage and administration; Gene expression; Genetic aspects; Humans; kinase; major depression; Mental disorders; Mental Disorders - drug therapy; Mental Disorders - genetics; Mental Disorders - psychology; Mental illness; Morphology; Oxidative stress; Phosphorylation; Psychotropic drugs; Psychotropic Drugs - pharmacology; Psychotropic Drugs - therapeutic use; psychotropic medication; Risk factors; Schizophrenia
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11203315

Astrocytes have many important functions in the brain, but their roles in psychiatric disorders and their responses to psychotropic medications are still being elucidated. Here, we used gene enrichment analysis to assess the relationships between different astrocyte subtypes, psychiatric diseases, and psychotropic medications (antipsychotics, antidepressants and mood stabilizers). We also carried out qPCR analyses and "look-up" studies to assess the chronic effects of these drugs on astrocyte marker gene expression. Our bioinformatic analysis identified gene enrichment of different astrocyte subtypes in psychiatric disorders. The highest level of enrichment was found in schizophrenia, supporting a role for astrocytes in this disorder. We also found differential enrichment of astrocyte subtypes associated with specific biological processes, highlighting the complex responses of astrocytes under pathological conditions. Enrichment of protein phosphorylation in astrocytes and disease was confirmed by biochemical analysis. Analysis of LINCS chemical perturbagen gene signatures also found that kinase inhibitors were highly discordant with astrocyte-SCZ associated gene signatures. However, we found that common gene enrichment of different psychotropic medications and astrocyte subtypes was limited. These results were confirmed by "look-up" studies and qPCR analysis, which also reported little effect of psychotropic medications on common astrocyte marker gene expression, suggesting that astrocytes are not a primary target of these medications. Conversely, antipsychotic medication does affect astrocyte gene marker expression in postmortem schizophrenia brain tissue, supporting specific astrocyte responses in different pathological conditions. Overall, this study provides a unique view of astrocyte subtypes and the effect of medications on astrocytes in disease, which will contribute to our understanding of their role in psychiatric disorders and offers insights into targeting astrocytes therapeutically.